A Tale Of Two Expectations: NDI Notification Estimate And Guidance
Regulatory Burden Notice Prompts Doubt While Hope Endures For Revised Draft
This article was originally published in The Tan Sheet
FDA’s estimates for supplement manufacturers’ burden for submitting NDI notifications continue to miss the mark widely, say trade group executives. The agency would be more on target, they say, with a revised draft guidance on NDI notifications expected to reflect stakeholders’ suggestions.
You may also be interested in...
A potential official list of pre-DSHEA dietary ingredients must allow adding more that are substantiated later, or it could spur class action litigation targeting ingredients not on the list. FDA announces topics for Oct. 3 public meeting on processes and policy for an authorized list of "old" ingredients.
Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.
Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims.